Objective ENACT aims to identify markers of response and tumour antigens that associate with ovarian and prostate cancer and melanoma progression and resistance to immunotherapy. Prospective clinical material will be collected during the life of the programme and new and existing tumour tissue, PBMC and serum banks will be available for use in the study. This common resource of material will be distributed to partners for the immunological, genomic, biochemical and proteomic analysis of tumour cells and host response(s) to immunotherapy. The results will be subjected to bioinformatic analysis in the context of clinical outcome of vaccine-based immunotherapy trials from 5 European clinical centres. Analysis of the results in the context of gender, will allow prominent inter- and intra- tumour/host biomarkers to be identified and translated back into clinical practice. The combined clinical and scientific expertise of the consortium provides added value and links with two on- going 5th Framework cancer programmes that will allow immediate access to melanoma patient data, tumour tissue and cell lines. This study promotes interdisciplinary translational research, which will offer a leading role to partners in 3 Eastern European NAS countries and in SMEs, and will provide a unique technology and science-driven platform for future expansion. We (the consortium) have extensive experience in the management and operation of 3rd-5th Framework projects and this current programme of research builds on previous experience and collaboration by many of the partners, but also increases the repertoire of scientific expertise by the inclusion of new partners, whose research skills are complimentary to the aims of ENACT. Fields of science medical and health sciencesclinical medicineoncologyprostate cancermedical and health sciencesclinical medicineoncologyskin cancermelanomamedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineimmunologyimmunotherapy Keywords biomarkers melanoma ovarian cancer prostate cancer tumour escape tumour progression Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2002-2.2.0-8 - Translational research on promising predictive and prognostic markers Call for proposal FP6-2002-LIFESCIHEALTH See other projects for this call Funding Scheme STREP - Specific Targeted Research Project Coordinator THE NOTTINGHAM TRENT UNIVERSITY EU contribution No data Address Burton Street NOTTINGHAM United Kingdom See on map Links Website Opens in new window Total cost No data Participants (13) Sort alphabetically Sort by EU Contribution Expand all Collapse all MEDICAL UNIVERSITY HOSPITAL "ALEXANDROVSKA" Bulgaria EU contribution No data Address Georgy Sofiiski 1 SOFIA See on map Total cost No data EBERHARD-KARLS-UNIVERSITÄT TÜBINGEN Germany EU contribution No data Address Wilhelmstr. 5 TÜBINGEN See on map Links Website Opens in new window Total cost No data KAROLINSKA INSTITUTET Sweden EU contribution No data Address Karolinska Institutet STOCKHOLM See on map Total cost No data JAGIELLONIAN UNIVERSITY, MEDICAL COLLEGE Poland EU contribution No data Address Sw. Anny 12 KRAKOW See on map Links Website Opens in new window Total cost No data UNIVERSITY OF LATVIA, BIOMEDICAL RESEARCH AND STUDY CENTRE Latvia EU contribution No data Address Ratsupites St 1 RIGA See on map Links Website Opens in new window Total cost No data FUNDACIÓN VIRGEN DE LAS NIEVES Spain EU contribution No data Address C/ Dr. Azpitarte s/n. Edificio Licinio de la Fuente GRANADA See on map Links Website Opens in new window Total cost No data DEUTSCHES KREBSFORSCHUNGSZENTRUM (GERMAN CANCER RESEARCH CENTER) Germany EU contribution No data Address Im Neuenheimer Feld 280 HEIDELBERG See on map Links Website Opens in new window Total cost No data THE NORWEGIAN RADIUM HOSPITAL HF Norway EU contribution No data Address Montebello OSLO See on map Links Website Opens in new window Total cost No data THE ANTHONY NOLAN TRUST United Kingdom EU contribution No data Address THE ROYAL FREE HOSPITAL POND ST HAMPSTEAD, LONDON See on map Links Website Opens in new window Total cost No data LOREUS LIMITED United Kingdom EU contribution No data Address Gervase J-Block, Clifton Campus, Clifton Lane, NOTTINGHAM See on map Links Website Opens in new window Total cost No data A'PESYP OF ATTICA-SAINT SAVAS CANCER HOSPITAL-CANCER IMMUNOLOGY AND IMMUNOTHERAPY CENTER Greece EU contribution No data Address 3,Zacharof str ATHENS See on map Total cost No data ONYVAX LTD United Kingdom EU contribution No data Address St Georges Hospital Medical School,Cranmer Terrace LONDON See on map Links Website Opens in new window Total cost No data INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France EU contribution No data Address 101 rue de Tolbiac PARIS See on map Links Website Opens in new window Total cost No data